Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:22 PM
Ignite Modification Date:
2025-12-24 @ 12:22 PM
NCT ID:
NCT03175861
Eligibility Criteria:
Inclusion Criteria:
* Age\> 18 years
* Performance Index WHO (World Health Organization) ≤ 2
* Bronchopulmonary carcinoma not in small cells proved histologically or cytologically (epidermoid, adenocarcinoma, or large cell carcinoma).
* Tumor classified T1 - T2 (Tumor=1-2) N0 (Node=0) M0 (Metastasis=0) and diameter ≤ 5 cm or Tumor classified T3 (≤5cm) N0M0 of the chest wall
* Tumor located more than 2 cm from the trachea and bronchus stem and more than 1.5 cm from the organs at risk
* Medically inoperable or refusing surgery
* Indication of stereotactic radiotherapy validated in multidisciplinary consultation meeting
* Formulation of consent
Exclusion Criteria:
* Age \<18 years.
* History of pulmonary irradiation
* Pulmonary surgery of the tumor
* Different histology of non-small cell carcinoma
* Patient with a T2 or T3\> 5 cm tumor or patients with a T3 tumor invading a structure other than the chest wall
* Patient with a tumor within 2 cm of the trachea and bronchus stem and within 1.5 cm of the organs at risk in the proximal area of the no fly zone (defined as a volume Located 2 cm in all directions of the proximal bronchial tree - Pulmonary metastases
* Declared pregnancy, breast-feeding
* Refusal to use effective contraception
* Against indication to the realization of the PET to the 18FDG (18-fluorodeoxyglucose)(uncontrolled diabetes)
* Refusal or inability to consent to participate in the study.
* Estimated life expectancy \<2 months in the absence of treatment
* Other invasive tumors diagnosed in the previous 2 years, with the exception of non-melanocytic cutaneous carcinomas.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03175861
Study Brief:
Protocol Section:
NCT03175861